ABOUT CJC-1295 MEDICINAL

What This Site Is

CJC-1295 Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295 (Modified GRF 1-29 / DAC:GRF). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'medicinal' modifier in this site's name signals the editorial position it occupies: a scholarly catalog of the pharmacological literature, written in the register of academic materia medica rather than clinical practice or commercial marketing. The site's design and typographic vocabulary — the neoclassical academic-plate aesthetic, the inscriptional typefaces, the engraving-style figures — are deliberate choices to frame the content as a museum-catalog entry in a study hall of molecular pharmacology, where a small but pharmacologically distinctive evidence base receives the gravity of careful scholarly documentation.

The domain modifier 'medicinal' does not imply that this site offers medicinal products, clinical services, or any form of treatment. It is editorial framing about how the compound is approached — with the gravity and restraint appropriate to unfinished research, not with the confidence of approved therapeutics.

Editorial Standards and Sourcing

Every quantitative claim on this site is attributed to a specific primary source from the peer-reviewed literature. Dose values, half-life estimates, study population characteristics, and pharmacodynamic measurements are cited at their point of use with inline reference markers linking to the full citation index on the References page.

The CJC-1295 evidence base is narrow: two randomized placebo-controlled Phase 1 trials in healthy adults, one animal normalization study, one proteomic characterization study, a collection of anti-doping analytical method papers spanning 2010 to 2025, and a netnographic observation study. We do not supplement this narrow primary literature with anecdotal accounts, forum claims, or unindexed secondary sources. Where the evidence is absent — efficacy in GH-deficient patients, long-term safety data, pediatric or geriatric pharmacokinetics — we say so explicitly.

Regulatory facts are presented as material information, not caveats. CJC-1295's status as a research chemical without approved therapeutic indication, its WADA S2 prohibition, and the discontinuation of its Phase 2 clinical program are documented throughout the site as core facts about the compound's standing rather than footnote warnings.

The site does not link to other domains in the same portfolio. The only outbound links on this site are to primary sources: PubMed, PMC, NIH, and peer-reviewed journal pages. These connections to primary literature are the epistemological foundation of the site's editorial project.

Disclaimer

CJC-1295 is not approved for human use by any regulatory agency, and it is classified as a research chemical. CJC-1295 Medicinal is an independent editorial project — not a clinic, not a vendor, not affiliated with any manufacturer or distributor. Nothing on this site constitutes medical advice, and nothing here should be read as a recommendation for any course of action. All content is editorial commentary on publicly available peer-reviewed research, conducted for academic and informational purposes.